← Back to All Filings

Spruce Biosciences ($SPRB) President/CFO in Stock Option Repricing

Medium SignificanceDecember 16, 2025

SPRUCE BIOSCIENCES, INC.

$SPRB4CIK: 0001683553

Filing Summary

Spruce Biosciences ($SPRB) President/CFO in Stock Option Repricing

Company: Spruce Biosciences, Inc. (SPRB) Form: 4 | Filed: 2025/12/15 Significance: Medium

Insider: Gharib Samir M. Title: PRESIDENT AND CFO | Relationship: Officer

Transaction: • Type: Option Repricing • Shares: 6,121 (underlying options) • Price: $0.00 • Value: $0 • Owned After: 6,121 (options)

Key Insight: The company repriced 6,121 outstanding stock options for its President/CFO, significantly lowering the exercise price to $104.13. This is a non-cash event intended to re-incentivize the executive.

Market Context: Option repricing typically follows a substantial decline in stock price. While it aligns executive interests with a future recovery, it can be viewed negatively by shareholders as it adjusts performance targets after losses have been incurred.

This is PUBLIC SEC data for educational purposes. Not investment advice.

Comprehensive Analysis

SEC Filing Analysis: Spruce Biosciences, Inc. (SPRB)

Executive Summary

  • Trading Significance: Medium
  • Key Takeaway: Spruce Biosciences repriced over 6,000 stock options for its President and CFO, drastically lowering the exercise price. This non-cash event is a significant corporate governance action reflecting past stock underperformance and an attempt to re-incentivize leadership.
  • Market Impact: The immediate market impact is likely neutral as no shares were bought or sold on the open market. However, it highlights the extent of the stock's prior decline.

Company Information

FieldValue
CompanySPRUCE BIOSCIENCES, INC.
Ticker SymbolSPRB
CIK0001683553
IndustryPHARMACEUTICAL PREPARATIONS

Insider Information

FieldValue
NameGharib Samir M.
CIK0001533302
Title/PositionPRESIDENT AND CFO
RelationshipOfficer

Transaction Details

FieldValue
Form Type4
Transaction Date2025-12-11
Transaction CodeA / D
Security TypeStock Option (Right to Buy)
Shares Involved6,121
Price Per Share$0.00
Total Value$0
Shares Owned After6,121 (derivative securities)
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$0
% of Market Cap0.0%
Shares Transacted6,121
% of Shares OutstandingN/A (data not available)
Post-Transaction Ownership6,121 derivative shares
Materiality AssessmentLow (by value), Medium (by event type)

Impact Evaluation

  • Market Cap Context: With a market cap of $110 million, any cash transaction would be noticeable. However, this $0 value transaction's significance lies not in its monetary value but in its strategic implication.
  • Ownership Concentration: The filing indicates the insider holds 6,121 options post-transaction. Without shares outstanding data, the ownership percentage cannot be determined.
  • Transaction Significance: The act of repricing options is a medium-significance event. It signals that previous performance targets (tied to higher stock prices) are now considered unattainable. The company is resetting incentives to align the CFO with achieving growth from the current, lower stock price. Original exercise prices were as high as $1,506, while the new price is $104.13, underscoring a major stock price decline.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: This is an administrative change to compensation structure, not a new investment or divestment by the insider. It reflects past negative performance rather than new information about future prospects.

Volume & Sentiment

  • Expected Volume Impact: Low. This is not a market transaction and should not directly influence trading volume.
  • Sentiment Indicator: Neutral. While it confirms past poor performance, it also shows the board is taking steps to retain and motivate key leadership for a potential turnaround.

Investment Insights

Positive Market Indicators

  • The repricing realigns the President/CFO's financial interests with a stock price recovery above the new $104.13 strike price.

Risk Factors

  • The need for a repricing signals that the company's stock has performed very poorly.
  • Shareholders may view this as poor corporate governance, as it effectively lowers the bar for executive compensation payouts after the stock has already fallen significantly.

Key Takeaways

  1. Incentive Reset: The primary purpose is to re-incentivize a key executive after a major stock price decline.
  2. Non-Cash Event: No money was exchanged, and no shares were traded on the open market. The impact is on governance and future compensation.
  3. Implicit Signal: The repricing implicitly acknowledges the company's stock is not expected to return to its previous highs in the near term.

Additional Context

Transaction Notes

  • Special Circumstances: As detailed in the filing's footnotes, this was a one-time stock option repricing. It was structured as a disposition (Code 'D') of the old, high-priced options and an acquisition (Code 'A') of new options at a lower exercise price of $104.13. The number of underlying shares and expiration dates remained unchanged.

Important Disclaimer

This analysis is for informational and educational purposes only and is NOT investment advice.

The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal.

Always consult with a qualified financial advisor before making any investment decisions.


Data Sources:

  • SEC EDGAR Filings (Official)
  • Analysis Generated: 2025-12-16

Join Our Community:


This post is automated and based on publicly available SEC EDGAR filings. All data is sourced directly from official SEC databases.

Topics:#SECFiling#SpruceBiosciences#SPRB#Form4#InsiderTrading#StockOptions#CorporateGovernance#Biotech#Investing#MarketAnalysis

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

⚠️ Important Disclaimer

This analysis is based on PUBLIC SEC data and is provided for educational and informational purposes ONLY. This is NOT investment advice, financial advice, or a recommendation to buy, sell, or hold any securities. The information presented should not be construed as a recommendation to take any action regarding any securities.

Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.